AR037096A1 - Compuestos de benzimidazol sustituido,composicion farmacologica que los comprende y uso de los mismos para la preparacion de una droga - Google Patents
Compuestos de benzimidazol sustituido,composicion farmacologica que los comprende y uso de los mismos para la preparacion de una drogaInfo
- Publication number
- AR037096A1 AR037096A1 ARP020103629A ARP020103629A AR037096A1 AR 037096 A1 AR037096 A1 AR 037096A1 AR P020103629 A ARP020103629 A AR P020103629A AR P020103629 A ARP020103629 A AR P020103629A AR 037096 A1 AR037096 A1 AR 037096A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- optionally substituted
- group
- alkoxy
- alkyl
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000008196 pharmacological composition Chemical class 0.000 title abstract 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical class C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000002252 acyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 239000002253 acid Chemical class 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- -1 benzimidazole compound Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 3
- 229920001774 Perfluoroether Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 108091007914 CDKs Proteins 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuesto de benzimidazol sustituidos de fórmula (1), donde: A es una entidad arilo o heteroarilo; donde R1 se selecciona entre uno o más grupos similares seleccionados entre: alquilo, eventualmente sustituido por un alcoxi, heteroalquilo, arilo, acilo, derivados de acilo, halógeno; alcoxi eventualmente sustituido por un alquilo, heteroalquilo, arilo, heteroarilo, alcoxialquilo, hidroxialquilo amida o un grupo perfluoroalcoxi o un alquiltio eventualmente sustituido por una amida o un perfluoroalquiltio; arilo o heteroarilo eventualmente sustituido por uno o más grupos alquilo, grupo alcoxi, grupo nitro, grupo ciano, derivado de acilo, grupo perfluoroalcoxi, grupo perfluoroalquilo, grupo heteroarilo, grupo ariloxi; halógeno; 4 NH2; 4 NH alquilo o cicloalquilo eventualmente sustituido con un acilo, un aciloderivado, un hidroxi, un grupo amino, alcoxi, heterociclilo o arilo; 4 N imidazolilo; 3 SO2Me cuando A es fenilo; donde R2 se selecciona entre el grupo que consiste en: CO-alquilo eventualmente sustituido por amino, ácido, derivado ácido, alcoxi, arilo o grupos OH; CO-aralquilo eventualmente sustituido por alcoxi, halógeno, amino, ácido o derivados de ácidos; CO-arilo eventualmente sustituido; CO-alcoxi eventualmente sustituido por arilo; CO-amino, CO-NHR3 CO-NR3R4 donde R3 y R4 se selecciona independientemente entre hidrógeno, alquilo, hidroxialquilo, alcoxialquilo fluoroalquilo, alcinilo, heteroalquilo, alquiheteroalquilo, arilo, aralquilo o en forma combinada entre una cadena alquileno que incluye eventualmente de 1 a 4 heteroátomos; arilo o aralquilo eventualmente sustituido por heterocicloalquilo, alquilo, arilo, alcoxi, amino, fluoroalquilo, derivados de acilo, halógeno; o una sal farmacológicamente aceptable o una prodroga de los mismos. Composición farmacológica que comprende una cantidad terapéuticamente efectiva de un compuesto de la fórmula (1) en combinación con un portador farmacológicamente aceptable. Uso de los compuestos de fórmula (1) para la preparación de una droga. Los compuestos de fórmula (1) actúan como inhibidores de las cinasas dependientes de la ciclina y resultan de utilidad en el tratamiento de patologías surgidas de la proliferación celular o exacerbada por ella.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01402460A EP1298125A1 (en) | 2001-09-26 | 2001-09-26 | Substituted benzimidazole compounds and their use for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037096A1 true AR037096A1 (es) | 2004-10-20 |
Family
ID=8182891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103629A AR037096A1 (es) | 2001-09-26 | 2002-09-26 | Compuestos de benzimidazol sustituido,composicion farmacologica que los comprende y uso de los mismos para la preparacion de una droga |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US7041668B2 (es) |
| EP (2) | EP1298125A1 (es) |
| JP (1) | JP4510450B2 (es) |
| KR (1) | KR100891439B1 (es) |
| CN (1) | CN100346786C (es) |
| AR (1) | AR037096A1 (es) |
| AT (1) | ATE386517T1 (es) |
| AU (1) | AU2002337151B2 (es) |
| BR (1) | BR0212856A (es) |
| CA (1) | CA2461622C (es) |
| CO (1) | CO5570675A2 (es) |
| CY (1) | CY1107953T1 (es) |
| DE (1) | DE60225159T2 (es) |
| DK (1) | DK1432417T3 (es) |
| EA (1) | EA006802B1 (es) |
| ES (1) | ES2301682T3 (es) |
| GT (1) | GT200200190A (es) |
| HR (1) | HRPK20040293B3 (es) |
| HU (1) | HUP0401756A3 (es) |
| IL (1) | IL161059A0 (es) |
| ME (1) | MEP16808A (es) |
| MX (1) | MXPA04002042A (es) |
| MY (1) | MY135339A (es) |
| NO (1) | NO327008B1 (es) |
| NZ (1) | NZ531246A (es) |
| PA (1) | PA8555501A1 (es) |
| PE (1) | PE20030427A1 (es) |
| PL (1) | PL369527A1 (es) |
| PT (1) | PT1432417E (es) |
| RS (1) | RS50896B (es) |
| SI (1) | SI1432417T1 (es) |
| UY (1) | UY27452A1 (es) |
| WO (1) | WO2003028721A2 (es) |
| ZA (1) | ZA200401887B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| AU2011250847B2 (en) * | 2003-06-23 | 2013-06-20 | Bhi Limited Partnership | Methods and compositions for treating amyloid-related diseases |
| EP1678121A4 (en) * | 2003-10-24 | 2007-07-25 | Exelixis Inc | MODULATORS OF TAO KINASES AND METHODS OF USE |
| DE102004010207A1 (de) | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
| FR2868421B1 (fr) * | 2004-04-01 | 2008-08-01 | Aventis Pharma Sa | Nouveaux benzothiazoles et leur utilisation comme medicaments |
| EP1598348A1 (en) | 2004-05-18 | 2005-11-23 | Aventis Pharma Deutschland GmbH | Novel pyridazinone derivatives as inhibitors of CDK2 |
| JP5145537B2 (ja) | 2004-12-22 | 2013-02-20 | ビーエイチアイ リミテッド パートナーシップ | アミロイド関連疾患を治療するための方法および組成物 |
| UA92180C2 (en) * | 2005-09-06 | 2010-10-11 | Смиткляйн Бичам Корпорейшн | Benzimidazole thiophene compounds as plk inhibitors |
| FR2891273B1 (fr) * | 2005-09-27 | 2007-11-23 | Aventis Pharma Sa | NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet |
| ES2967330T3 (es) | 2006-10-12 | 2024-04-29 | Bellus Health Inc | Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| CN101821270A (zh) * | 2007-10-12 | 2010-09-01 | 雅培制药有限公司 | 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形1 |
| FR2922550B1 (fr) | 2007-10-19 | 2009-11-27 | Sanofi Aventis | Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet |
| FR2941951B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941950B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941952B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941949B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| WO2011091152A1 (en) * | 2010-01-22 | 2011-07-28 | Pablo Gastaminza | Inhibitors of hepatitis c virus infection |
| WO2014089313A1 (en) | 2012-12-05 | 2014-06-12 | Alnylam Pharmaceuticals | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| CN114939124A (zh) | 2015-08-25 | 2022-08-26 | 阿尔尼拉姆医药品有限公司 | 治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2441201C2 (de) * | 1974-08-28 | 1986-08-07 | Hoechst Ag, 6230 Frankfurt | Anthelminthisch wirksame 2-Carbalkoxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole und Verfahren zu ihrer Herstellung |
| DE2541752A1 (de) | 1975-09-19 | 1977-03-24 | Hoechst Ag | Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung |
| DE3247615A1 (de) * | 1982-12-23 | 1984-07-05 | Hoechst Ag, 6230 Frankfurt | Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| GB9900752D0 (en) * | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| US6693125B2 (en) * | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
-
2001
- 2001-09-26 EP EP01402460A patent/EP1298125A1/en not_active Withdrawn
-
2002
- 2002-09-17 PE PE2002000913A patent/PE20030427A1/es not_active Application Discontinuation
- 2002-09-24 UY UY27452A patent/UY27452A1/es unknown
- 2002-09-25 MY MYPI20023586A patent/MY135339A/en unknown
- 2002-09-25 GT GT200200190A patent/GT200200190A/es unknown
- 2002-09-26 IL IL16105902A patent/IL161059A0/xx unknown
- 2002-09-26 PT PT02772370T patent/PT1432417E/pt unknown
- 2002-09-26 WO PCT/EP2002/011353 patent/WO2003028721A2/en not_active Ceased
- 2002-09-26 EA EA200400475A patent/EA006802B1/ru not_active IP Right Cessation
- 2002-09-26 SI SI200230686T patent/SI1432417T1/sl unknown
- 2002-09-26 PA PA20028555501A patent/PA8555501A1/es unknown
- 2002-09-26 EP EP02772370A patent/EP1432417B1/en not_active Expired - Lifetime
- 2002-09-26 HR HR20040293A patent/HRPK20040293B3/xx not_active IP Right Cessation
- 2002-09-26 CA CA002461622A patent/CA2461622C/en not_active Expired - Fee Related
- 2002-09-26 CN CNB028187458A patent/CN100346786C/zh not_active Expired - Fee Related
- 2002-09-26 AU AU2002337151A patent/AU2002337151B2/en not_active Ceased
- 2002-09-26 HU HU0401756A patent/HUP0401756A3/hu unknown
- 2002-09-26 NZ NZ531246A patent/NZ531246A/en not_active IP Right Cessation
- 2002-09-26 PL PL02369527A patent/PL369527A1/xx not_active Application Discontinuation
- 2002-09-26 AT AT02772370T patent/ATE386517T1/de active
- 2002-09-26 ME MEP-168/08A patent/MEP16808A/xx unknown
- 2002-09-26 DE DE60225159T patent/DE60225159T2/de not_active Expired - Lifetime
- 2002-09-26 KR KR1020047004365A patent/KR100891439B1/ko not_active Expired - Fee Related
- 2002-09-26 AR ARP020103629A patent/AR037096A1/es unknown
- 2002-09-26 DK DK02772370T patent/DK1432417T3/da active
- 2002-09-26 ES ES02772370T patent/ES2301682T3/es not_active Expired - Lifetime
- 2002-09-26 RS YUP-214/04A patent/RS50896B/sr unknown
- 2002-09-26 JP JP2003532053A patent/JP4510450B2/ja not_active Expired - Fee Related
- 2002-09-26 MX MXPA04002042A patent/MXPA04002042A/es active IP Right Grant
- 2002-09-26 BR BR0212856-0A patent/BR0212856A/pt not_active IP Right Cessation
-
2004
- 2004-03-08 ZA ZA200401887A patent/ZA200401887B/en unknown
- 2004-03-23 NO NO20041214A patent/NO327008B1/no not_active IP Right Cessation
- 2004-03-25 CO CO04028337A patent/CO5570675A2/es not_active Application Discontinuation
- 2004-03-25 US US10/808,889 patent/US7041668B2/en not_active Expired - Fee Related
-
2008
- 2008-05-20 CY CY20081100526T patent/CY1107953T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037096A1 (es) | Compuestos de benzimidazol sustituido,composicion farmacologica que los comprende y uso de los mismos para la preparacion de una droga | |
| AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
| RU2498980C2 (ru) | Новое производное 1,2,3,4-тетрагидрохиноксалина, содержащее в качестве заместителя фенильную группу, имеющую структуру эфира сульфокислоты или амида сульфокислоты, и обладающее связывающей активностью в отношении рецептора глюкокортикоидов | |
| AR053232A1 (es) | Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico. | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR055057A1 (es) | Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria. | |
| AR072792A1 (es) | DERIVADOS DE PIRROLOPIRIDINILPIRIMIDIN-2-IL-AMINA, PROCEDIMIENTO DE PREPARACIoN Y COMPOSICIONES FARMACEUTICAS | |
| PE20071322A1 (es) | Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa | |
| PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
| AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
| PE20070855A1 (es) | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20110150A1 (es) | Amidofenoxiindazoles como inhibidores de c-met | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| PE20080315A1 (es) | DERIVADOS DE PIRAZOLO-[3,4-d]-PIRIMIDINAS COMO INHIBIDORES DE CINASA PI-3 | |
| PE20020406A1 (es) | 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6-DISUSTITUIDAS COMO INHIBIDORES DE LAS PROTEINAS CINASAS | |
| BR0008770A (pt) | Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica | |
| PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
| AR046200A1 (es) | Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| AR079497A1 (es) | Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a | |
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| CY1107677T1 (el) | Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine | |
| PE20090880A1 (es) | Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa | |
| PE20090216A1 (es) | Compuestos triazolil aminopirimidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |